Pharma Stock With Revenue CAGR Outlook of Up to 20% to Keep on Your Radar

Synopsis: A healthcare stock with Rs 556 Cr Q3 revenue, strong CRDMO, CRO, and CDMO growth, healthy pipeline, and 18–20 percent revenue CAGR remains a key pick for investors tracking long-term growth opportunities.

This article outlines a leading pharma stock with strong CRDMO, CRO, and CDMO businesses, highlighting recent financial performance, strategic capex, and robust pipeline growth. It examines long-term revenue and margin outlook, business momentum, and brokerage views, providing insights for investors tracking high-growth healthcare opportunities.

With a market capitalization of Rs 20,921 crore, Sai Life Sciences Ltd’s share is trading at current levels of Rs 987 per share, down by 2.21 percent from its previous day’s close price. The share of this company has given a return of 41 percent over the last 1 years.

Business Capex and Expansion

The company has invested Rs405 Cr of the planned Rs700 Cr capex for FY26, focusing on R&D and manufacturing expansion. Key initiatives include commissioning additional MedChem capacity with 200 fume hoods in Q4FY26, completing the Process R&D Lab structure by September 2026, and expanding peptide process and pilot plants.

Manufacturing growth is on track with 450KL capacity expansion; the first 225 KL production block will be ready by Q2FY27, and the second by FY27 end. Phase I of Animal Health expansion is expected to be completed by March 2027, after which commercial validation will begin, supporting future growth.

Strong Revenue and Margin Outlook: The company expects long-term revenue growth of 18 to 20 percent CAGR, supported by operating leverage, an improved product mix, and enhanced process efficiencies. EBITDA margins are projected to remain healthy at 28–30 percent, reflecting disciplined cost management and scalable business operations across its R&D and manufacturing segments.

Business Momentum Across CRO and CDMO Segments

CRO Business Growth: The CRO business continues its strong growth trajectory, driven by deeper engagements with large global pharma clients. Strategic investments in discovery technologies are accelerating capabilities, positioning the company to capture a larger share of high-value projects and sustain long-term momentum.

CDMO Segment Performance: The CDMO segment remains robust, with over 90 percent of revenue from pharma clients. Seven new molecules were added during the year, expanding the late-phase and commercial pipeline to 43 molecules, helping the business offset volume variability and strengthen its long-term growth prospects.

Brokerage View on Sai Life Sciences

Jefferies maintains a Buy rating on Sai Life Sciences, raising the target price to Rs 1,300 from Rs 1,180, implying a 31 percent upside. The brokerage highlights the company as a top pick in the CRDMO space, supported by a robust integrated “follow-the-molecule” business model.

Strong Growth Drivers

The firm’s healthy pipeline and strong win rates underpin a positive growth outlook. Presence in oligos and an expanding global footprint further enhance potential, allowing Sai Life Sciences to capture high-value contracts and sustain long-term momentum across its CRDMO operations.

Valuation and Estimates

Sai Life Sciences benefits from a clean balance sheet with no private equity supply overhang. Jefferies notes valuations are in line with peers despite strong growth. Accordingly, FY28 sales and EPS estimates have been raised by 3 percent and 5 percent, reflecting confidence in continued financial performance.

About the Company

Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in the pharmaceutical and biotechnology industries. It is a rapidly growing, Hyderabad-based Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end small molecule services for pharma and biotech industries.

Financial Highlights: The revenue from operations grew by 27 percent to Rs 556 crore in Q3 FY26 from Rs 440 crore in Q3 FY25. EBIDT grew by 54 percent to Rs 191 crore in Q3 FY26 from Rs 124 crore in Q3 FY25. Accompanied by a net profit growth of 86 percent to Rs 100 crore in Q3 FY26 from Rs 54 crore in Q3 FY25, resulting in an EPS growth of 88 percent to Rs 4.77 per share in Q3 FY26

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock With Revenue CAGR Outlook of Up to 20% to Keep on Your Radar appeared first on Trade Brains.